Barnes, Geoffrey D.
Misirliyan, Sevan
Kaatz, Scott
Jackson, Elizabeth A.
Haymart, Brian
Kline-Rogers, Eva
Kozlowski, Jay
Krol, Gregory
Froehlich, James B.
Sales, Anne
Funding for this research was provided by:
Blue Cross Blue Shield of Michigan
National Heart, Lung, and Blood Institute (2-T32-HL007853)
Article History
Received: 19 January 2017
Accepted: 5 July 2017
First Online: 14 July 2017
Ethics approval and consent to participate
: This study was reviewed by the University of Michigan Institutional Review Board and deemed not regulated as a quality improvement project.
: Not applicable.
: GB reports research grant funding from Blue Cross-Blue Shield of Michigan and Pfizer/BMS. He reports consulting fees from Aralez and Pfizer/BMS.SM reports no competing interestsSK reports speaker honorarium from Janssen, Boehringer-Ingelheim, Bristol Myer Squibb, Pfizer, CSL Behring, Daiichi Sankyo; consultant fees from Boehringer Ingelheim, Bristol Myer Squibb, Pfizer, JanssenDaiichi Sankyo, Portola. Research funding (to institution): JanssenLAJ reports no competing interestsBH reports no competing interestsEKR reports consulting fees from Janssen and board membership in the Anticoagulation ForumJK reports no competing interestsGK reports no competing interestsJBF Consultant: Boehringer Ingelheim, Bristol Myer Squibb, Pfizer, Janssen, Merck. Research Funding: Janssen, Pfizer, Blue Cross-Blue Shield of MichiganAS reports serving and co-editor-in-chief for Implementation Science
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.